INVA
Innoviva, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2004-10-05
$20.93
-0.09 (-0.43%)
last quote
Want the full multi-source brief on INVA?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$20.93
High
$21.39
Low
$20.90
Previous close
$21.02
Fundamentals
Market cap
$1.52B
P/E (TTM)
4.26x
P/S (TTM)
3.46x
P/B
1.27x
Gross margin
72.19%
Operating margin
36.95%
Net margin
81.19%
Rev growth (YoY)
18.84%
EPS growth (YoY)
1744.60%
ROE
30.03%
52W high
$25.15
52W low
$17.77
Beta
0.38x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-11in 6 days
Q3 2026EPS est $0.53Rev est $117.6M
Recent SEC filings
CIK 1080014filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
Pfizer (PFE) delivered earnings and revenue surprises of +20.83% and +2.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 5d
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 6d
Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue Estimates
Lilly (LLY) delivered earnings and revenue surprises of +39.03% and +10.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial